12 May 2025 Date | | - Cons. EPS | - EPS |
31 Mar 2025 Date | | - Cons. EPS | - EPS |
11 Nov 2024 Date | | - Cons. EPS | - EPS |
14 Aug 2024 Date | | - Cons. EPS | - EPS |
13 Aug 2024 Date | | - Cons. EPS | - EPS |
12 May 2025 Date | | - Cons. EPS | - EPS |
31 Mar 2025 Date | | - Cons. EPS | - EPS |
11 Nov 2024 Date | | - Cons. EPS | - EPS |
14 Aug 2024 Date | | - Cons. EPS | - EPS |
13 Aug 2024 Date | | - Cons. EPS | - EPS |
Specialty Chemicals Industry | Basic Materials Sector | Mr. Kim Kraig Thompson CEO | OTCQB Exchange | US50075W1045 ISIN |
US Country | 37 Employees | - Last Dividend | 28 May 2009 Last Split | - IPO Date |
Kraig Biocraft Laboratories, Inc. is a pioneering company focused on the development of protein-based fibers for a broad range of commercial applications within the technical textile and specialty fiber industries. Founded in 2006 and headquartered in Ann Arbor, Michigan, the company harnesses recombinant DNA technology to innovate in the field of biotechnology. Its research efforts are primarily centered around the production of natural and engineered variants of spider silk, utilizing domesticated mulberry silkworms that have been genetically modified to produce spider silk proteins. This cutting-edge technology aims to create recombinant spider silk fibers that boast superior strength, flexibility, and a wide array of applications, from military and defense to medical textiles.
The product line of Kraig Biocraft Laboratories, Inc. extends across various industries, leveraging the unique properties of spider silk for diverse applications: